Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine?

Greenwich LifeSciences Inc. (NASDAQ:GLSI) stock is trading higher on Monday, with a session volume of 2.804 million compared to the average volume of 81.85 thousand, as per data from Benzinga Pro.Greenwich LifeSciences on Monday said its Phase 3 trial FLAMINGO-01, evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, showed an approximately 80% recurrence rate reduction in the 220-patient open-label non-HLA-A*02 arm of FLAMINGO-01.The observation is trending similarly to the Phase 2b t ...